An article from CBS.MarketWatch.com

[Guest guest]

This is disgusting. Expect to see more glitzy TV ads in places where there is a high concentration of Hispanic or African Americans. Have these people NO SHAME??? Maybe there'll be an outbreak of Legionaires Disease or some other contagion that will do away with all these pharmaceutical parasites.

[Guest guest]

This is disgusting. Expect to see more glitzy TV ads in places where there is a high concentration of Hispanic or African Americans. Have these people NO SHAME??? Maybe there'll be an outbreak of Legionaires Disease or some other contagion that will do away with all these pharmaceutical parasites.

[Guest guest]

It is too bad. If more of ethnicities become convinced that the

pharmaceuticals are our friends, then more people will fall

into the pharmaceutical fraud.

Suzy

>From: <PaySDPayne@...>

>Reply-SSRI medications

> " SSRI medications " <SSRI medications >

>Subject: An article from CBS.MarketWatch.com

>Date: Fri, 15 Feb 2002 01:54:56 " GMT "

>

_________________________________________________________________

Join the world’s largest e-mail service with MSN Hotmail.

http://www.hotmail.com

This story was sent to you by PaySDPayne@... with these comments:

From CBS.MarketWatch.com, online at:http://cbs.marketwatch.com/tools/quotes/newsarticle.asp?guid={4486A94A-CA67-47B1-92BB-C3118DB20474}&siteid=mktw&dist=nbs

CBS.MarketWatch.com

Quotes & News

symbol/fund/keyword

Find Symbol

Latest Market Overview

2/14/2002 12:57:00 PM

Pharma Companies Meet in Princeton to Discuss Multicultural DTC & OTC Marketing, Media & PR Strategies at 3rd Annual Conference on March 4-5, 2002

NEW YORK, Feb 14, 2002 /PRNewswire via COMTEX/ -- Strategic Research Institute

New York is hosting the 3rd Annual Multicultural Pharmaceutical Marketing

conference designed for the pharmaceutical industry. Participating firms include

GlaxoKline, Pfizer, Eli Lilly, Aventis, Pharmacia, McNeil Consumer &

Specialty Products, Wyeth Corporation, Wakefern, Walgreen Company and H & R Block.

Speakers include GlaxoKline's J. Mullens, Director of Medical

marketing, Pfizer's Kalfus and & 's Anne Zuckerman.The conference will help marketers understand how reach out to the fast growing

African-American, Hispanic-American and Asian-American segments by providing

information about various drugs and very importantly also convey appropriately

designed and channeled health education. The sessions will feature an array

pharmaceutical marketers who have taken initiatives in this area as well as

seasoned multicultural experts who have successfully helped a variety of other

industries tap into the under-served needs of ethnic consumers whose buying

power now exceeds $1.2 Trillion. Also present will be representatives from

not-for-profit associations like the National Kidney Foundation and the American

Podiatric Medical Association who can help forge valuable links with

communities.Program Highlights Include:* Five Insightful Keynote Sessions by Professor N. Parrillo,Immigration and Race Relations Expert and Chair of Sociology, at Paterson University* A. Levy, Ph.D., VP Scientific Affairs, National PharmaceuticalCouncil* Ingrid-Otero Smart, President Elect of Association of Hispanic AdAgencies, and President of MD & A Salud* Matt Giegerich, President and CEO of CommonHealth* Nick Brien, Chairman, StarComMediaVest GroupPresentations from H & RBlock's Ayala, Leroy Abrams for Don- Yankelovich AfricanAmerican Monitor, Santiago Valdes Solutions, IMAGES USA, Kang & Lee,Lumina Americas, Fleishman-Hillard, American Legacy Magazine,AsianAvenue.com, EDirect, Makinita LLC, BlackVoices.com and morePlus!United States Census Bureau to share latest information on Mining the Census

2000 Data and Ethnic Media and ROI Workshop & Valuable Post Conference Workshop

session on Measuring ROI on Multicultural Grassroots Marketing.Call to register at 1-888-666-8514 or visit http://www.srinstitute.com/cm372.

For more information contact Rupa Ranganathan at 212-967-0095x252 or send email

to rranganathan@.... Please mention keycode DPR000364 when

registering.MAKE YOUR OPINION COUNT -Click Herehttp://tbutton.prnewswire.com/prn/11690X36122843SOURCE Strategic Research InstituteCONTACT:Rupa Ranganathan of the Strategic Research Institute,+1-212-967-0095, ext. 252, rranganathan@...URL:http://www.srinstitute.comhttp://www.prnewswire.comCopyright © 2002 PR Newswire. All rights reserved.

4:30 pm ET Feb 14, 2002

DJIA

10001.99 +12.32

NASDAQ

1843.37 -15.79

SP500

1116.48 -2.03

10Yr

4.959% -0.044

Front Page News

Dell hits target, shares stall

Dell's fourth-quarter results as expected

Enron's Watkins: Lay and board were 'duped'

Dow ends at 10k while Nasdaq buyers lose interest

Intraday data provided by S & P Comstock and subject to terms of use.Historical and current end-of-day data provided by FT Interactive Data..

[Guest guest]

It is too bad. If more of ethnicities become convinced that the

pharmaceuticals are our friends, then more people will fall

into the pharmaceutical fraud.

Suzy

>From: <PaySDPayne@...>

>Reply-SSRI medications

> " SSRI medications " <SSRI medications >

>Subject: An article from CBS.MarketWatch.com

>Date: Fri, 15 Feb 2002 01:54:56 " GMT "

>

_________________________________________________________________

Join the world’s largest e-mail service with MSN Hotmail.

http://www.hotmail.com

This story was sent to you by PaySDPayne@... with these comments:

From CBS.MarketWatch.com, online at:http://cbs.marketwatch.com/tools/quotes/newsarticle.asp?guid={4486A94A-CA67-47B1-92BB-C3118DB20474}&siteid=mktw&dist=nbs

CBS.MarketWatch.com

Quotes & News

symbol/fund/keyword

Find Symbol

Latest Market Overview

2/14/2002 12:57:00 PM

Pharma Companies Meet in Princeton to Discuss Multicultural DTC & OTC Marketing, Media & PR Strategies at 3rd Annual Conference on March 4-5, 2002

NEW YORK, Feb 14, 2002 /PRNewswire via COMTEX/ -- Strategic Research Institute

New York is hosting the 3rd Annual Multicultural Pharmaceutical Marketing

conference designed for the pharmaceutical industry. Participating firms include

GlaxoKline, Pfizer, Eli Lilly, Aventis, Pharmacia, McNeil Consumer &

Specialty Products, Wyeth Corporation, Wakefern, Walgreen Company and H & R Block.

Speakers include GlaxoKline's J. Mullens, Director of Medical

marketing, Pfizer's Kalfus and & 's Anne Zuckerman.The conference will help marketers understand how reach out to the fast growing

African-American, Hispanic-American and Asian-American segments by providing

information about various drugs and very importantly also convey appropriately

designed and channeled health education. The sessions will feature an array

pharmaceutical marketers who have taken initiatives in this area as well as

seasoned multicultural experts who have successfully helped a variety of other

industries tap into the under-served needs of ethnic consumers whose buying

power now exceeds $1.2 Trillion. Also present will be representatives from

not-for-profit associations like the National Kidney Foundation and the American

Podiatric Medical Association who can help forge valuable links with

communities.Program Highlights Include:* Five Insightful Keynote Sessions by Professor N. Parrillo,Immigration and Race Relations Expert and Chair of Sociology, at Paterson University* A. Levy, Ph.D., VP Scientific Affairs, National PharmaceuticalCouncil* Ingrid-Otero Smart, President Elect of Association of Hispanic AdAgencies, and President of MD & A Salud* Matt Giegerich, President and CEO of CommonHealth* Nick Brien, Chairman, StarComMediaVest GroupPresentations from H & RBlock's Ayala, Leroy Abrams for Don- Yankelovich AfricanAmerican Monitor, Santiago Valdes Solutions, IMAGES USA, Kang & Lee,Lumina Americas, Fleishman-Hillard, American Legacy Magazine,AsianAvenue.com, EDirect, Makinita LLC, BlackVoices.com and morePlus!United States Census Bureau to share latest information on Mining the Census

2000 Data and Ethnic Media and ROI Workshop & Valuable Post Conference Workshop

session on Measuring ROI on Multicultural Grassroots Marketing.Call to register at 1-888-666-8514 or visit http://www.srinstitute.com/cm372.

For more information contact Rupa Ranganathan at 212-967-0095x252 or send email

to rranganathan@.... Please mention keycode DPR000364 when

registering.MAKE YOUR OPINION COUNT -Click Herehttp://tbutton.prnewswire.com/prn/11690X36122843SOURCE Strategic Research InstituteCONTACT:Rupa Ranganathan of the Strategic Research Institute,+1-212-967-0095, ext. 252, rranganathan@...URL:http://www.srinstitute.comhttp://www.prnewswire.comCopyright © 2002 PR Newswire. All rights reserved.

4:30 pm ET Feb 14, 2002

DJIA

10001.99 +12.32

NASDAQ

1843.37 -15.79

SP500

1116.48 -2.03

10Yr

4.959% -0.044

Front Page News

Dell hits target, shares stall

Dell's fourth-quarter results as expected

Enron's Watkins: Lay and board were 'duped'

Dow ends at 10k while Nasdaq buyers lose interest

Intraday data provided by S & P Comstock and subject to terms of use.Historical and current end-of-day data provided by FT Interactive Data..

[Guest guest]

Anyone want to protest with me???

I can be there...

Lynn

[Guest guest]

Anyone want to protest with me???

I can be there...

Lynn

[Guest guest]

Sure,

Suzy

>From: " nirenbergl " <nirenbergl@...>

>Reply-SSRI medications

>SSRI medications

>Subject: Re: An article from CBS.MarketWatch.com

>Date: Fri, 15 Feb 2002 03:07:56 -0000

>

>Anyone want to protest with me???

>

>I can be there...

>

>Lynn

>

_________________________________________________________________

MSN Photos is the easiest way to share and print your photos:

http://photos.msn.com/support/worldwide.aspx

[Guest guest]

Sure,

Suzy

>From: " nirenbergl " <nirenbergl@...>

>Reply-SSRI medications

>SSRI medications

>Subject: Re: An article from CBS.MarketWatch.com

>Date: Fri, 15 Feb 2002 03:07:56 -0000

>

>Anyone want to protest with me???

>

>I can be there...

>

>Lynn

>

_________________________________________________________________

MSN Photos is the easiest way to share and print your photos:

http://photos.msn.com/support/worldwide.aspx

[Guest guest]

This story was sent to you by PaySDPayne@... with these comments:

From CBS.MarketWatch.com, online at:http://cbs.marketwatch.com/tools/quotes/newsarticle.asp?guid={3CBF898B-2DA2-4203-8901-5DF08B4E4D38}&siteid=mktw&dist=nbs

CBS.MarketWatch.com

Quotes & News

symbol/fund/keyword

Find Symbol

Latest Market Overview

3/5/2002 3:11:00 PM

Sales of Lilly Blood Drug Slow

INDIANAPOLIS, Mar 05, 2002 (AP Online via COMTEX) -- Sales of Xigris, the

breakthrough blood-infection drug expected to help rebuild Eli Lilly & Co.

revenues after losing its Prozac patent, have had a slow start as hospitals

adjust to the sometimes tricky task of when to use it.Xigris sales through February were about $14 million, bringing total sales since

the sepsis drug's launch last November to about $35 million, the

Indianapolis-based drug maker said Monday."Some challenges have affected the initial uptake of Xigris," said E.

Golden, Lilly's executive vice president and chief financial officer.Those challenges included delays caused by the lack of treatment protocols at

some larger hospitals, he said.Xigris is a biologically engineered form of a natural blood product that is the

first FDA-approved drug to directly attack the inflammation and blood clots

accompanying sepsis, a deadly bloodstream infection that kills thousands of

hospital patients each year.The FDA approved Xigris for use only for sepsis patients deemed least likely to

survive. Selecting those patients has proven complex for physicians initially,

Golden said."However, for hospitals that have used Xigris, reorder rates have been robust

because, once physicians use Xigris, they tend to use it again," he said.As a result, he said, Lilly anticipates a steady increase in Xigris sales during

2002."We believe Xigris will become a great commercial success," Golden said.Xigris is one of a handful of new drugs Lilly is counting on to offset declining

revenues for its former top seller, the anti-depressant Prozac.Prozac sales dropped 84 percent for the fourth quarter of 2001 as doctors and

health insurance plans encouraged patients to switch to a cheaper generic pill.

Lilly lost its patent protection on Prozac last August.Compensation for Lilly executives dropped as much as 50 percent last year

because of the loss of some $600 million in annual Prozac sales, according to a

proxy statement Lilly filed Monday with the Securities and Exchange Commission.Sidney Taurel, chairman, president and chief executive, saw a 29 percent drop in

overall compensation from 2000 to 2001. He received a bonus last year of

$474,366, down from $1.49 million in 2000, with his salary rising to $1.39

million from $1.3 million the prior year.Chief financial officer Golden's bonus fell to $183,569 from $592,442 in

2000. His salary climbed to $789,540 in 2001 from $759,540 the prior year.August M. Watanabe, executive vice president for science and technology,

received $1.77 million in total compensation last year, a 26 percent decline

from the 2000.Lilly also has frozen salaries for its employees in 2002 at 2001 levels, and

Taurel has said that he will receive only $1 in salary for the year.Shares of Lilly fell $1.45 to $77.05 in afternoon trading Tuesday on the New

York Stock Exchange.---On the Net:Copyright 2002 Associated Press, All rights reserved

Mar 6, 2002

DJIA

10574.29 +140.88

NASDAQ

1890.4 +24.11

SP500

1162.77 +16.63

10Yr

5.032% +0.24

Front Page News

Microsoft lower on Xbox concerns, most techs up

FTC approves H-P-Compaq deal, won't require spinoffs

Wall Street firms asked to detail ties to Enron

Enron's interim CEO confident of a turnaround

Intraday data provided by S & P Comstock and subject to terms of use.Historical and current end-of-day data provided by FT Interactive Data..

[Guest guest]

This story was sent to you by PaySDPayne@... with these comments:

From CBS.MarketWatch.com, online at:http://cbs.marketwatch.com/tools/quotes/newsarticle.asp?guid={3CBF898B-2DA2-4203-8901-5DF08B4E4D38}&siteid=mktw&dist=nbs

CBS.MarketWatch.com

Quotes & News

symbol/fund/keyword

Find Symbol

Latest Market Overview

3/5/2002 3:11:00 PM

Sales of Lilly Blood Drug Slow

INDIANAPOLIS, Mar 05, 2002 (AP Online via COMTEX) -- Sales of Xigris, the

breakthrough blood-infection drug expected to help rebuild Eli Lilly & Co.

revenues after losing its Prozac patent, have had a slow start as hospitals

adjust to the sometimes tricky task of when to use it.Xigris sales through February were about $14 million, bringing total sales since

the sepsis drug's launch last November to about $35 million, the

Indianapolis-based drug maker said Monday."Some challenges have affected the initial uptake of Xigris," said E.

Golden, Lilly's executive vice president and chief financial officer.Those challenges included delays caused by the lack of treatment protocols at

some larger hospitals, he said.Xigris is a biologically engineered form of a natural blood product that is the

first FDA-approved drug to directly attack the inflammation and blood clots

accompanying sepsis, a deadly bloodstream infection that kills thousands of

hospital patients each year.The FDA approved Xigris for use only for sepsis patients deemed least likely to

survive. Selecting those patients has proven complex for physicians initially,

Golden said."However, for hospitals that have used Xigris, reorder rates have been robust

because, once physicians use Xigris, they tend to use it again," he said.As a result, he said, Lilly anticipates a steady increase in Xigris sales during

2002."We believe Xigris will become a great commercial success," Golden said.Xigris is one of a handful of new drugs Lilly is counting on to offset declining

revenues for its former top seller, the anti-depressant Prozac.Prozac sales dropped 84 percent for the fourth quarter of 2001 as doctors and

health insurance plans encouraged patients to switch to a cheaper generic pill.

Lilly lost its patent protection on Prozac last August.Compensation for Lilly executives dropped as much as 50 percent last year

because of the loss of some $600 million in annual Prozac sales, according to a

proxy statement Lilly filed Monday with the Securities and Exchange Commission.Sidney Taurel, chairman, president and chief executive, saw a 29 percent drop in

overall compensation from 2000 to 2001. He received a bonus last year of

$474,366, down from $1.49 million in 2000, with his salary rising to $1.39

million from $1.3 million the prior year.Chief financial officer Golden's bonus fell to $183,569 from $592,442 in

2000. His salary climbed to $789,540 in 2001 from $759,540 the prior year.August M. Watanabe, executive vice president for science and technology,

received $1.77 million in total compensation last year, a 26 percent decline

from the 2000.Lilly also has frozen salaries for its employees in 2002 at 2001 levels, and

Taurel has said that he will receive only $1 in salary for the year.Shares of Lilly fell $1.45 to $77.05 in afternoon trading Tuesday on the New

York Stock Exchange.---On the Net:Copyright 2002 Associated Press, All rights reserved

Mar 6, 2002

DJIA

10574.29 +140.88

NASDAQ

1890.4 +24.11

SP500

1162.77 +16.63

10Yr

5.032% +0.24

Front Page News

Microsoft lower on Xbox concerns, most techs up

FTC approves H-P-Compaq deal, won't require spinoffs

Wall Street firms asked to detail ties to Enron

Enron's interim CEO confident of a turnaround

Intraday data provided by S & P Comstock and subject to terms of use.Historical and current end-of-day data provided by FT Interactive Data..